Disability and progression in Afro-descendant patients with multiple sclerosis

Juliana Calvet Kallenbach Aurenção; Claudia Cristina Ferreira Vasconcelos; Luiz Claudio Santos Thuler; Regina Maria Papais Alvarenga

doi:10.1590/0004-282X20160118

Arquivos de Neuro-Psiquiatria, Table of Contents

CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2016; 74(10): 836-841
DOI: 10.1590/0004-282X20160118

VIEW AND REVIEW

Disability and progression in Afro-descendant patients with multiple sclerosis

Incapacidade e progressão em pacientes afrodescendentes com esclerose múltipla

Authors

Juliana Calvet Kallenbach Aurenção

¹Universidade Federal do Estado do Rio de Janeiro, Hospital Universitário Gaffrée e Guinle, Rio de Janeiro RJ, Brasil;
Claudia Cristina Ferreira Vasconcelos

¹Universidade Federal do Estado do Rio de Janeiro, Hospital Universitário Gaffrée e Guinle, Rio de Janeiro RJ, Brasil;
Luiz Claudio Santos Thuler

¹Universidade Federal do Estado do Rio de Janeiro, Hospital Universitário Gaffrée e Guinle, Rio de Janeiro RJ, Brasil;

²Instituto Nacional de Câncer - INCA, Rio de Janeiro RJ, Brasil;
Regina Maria Papais Alvarenga

¹Universidade Federal do Estado do Rio de Janeiro, Hospital Universitário Gaffrée e Guinle, Rio de Janeiro RJ, Brasil;

³Hospital Federal da Lagoa, Rio de Janeiro RJ, Brasil.

Abstract

ABSTRACT

Multiple sclerosis (MS) prevalence is higher in Caucasian (CA) populations, narrowing the analysis of the impact of Afro-descendant (AD) populations in disease outcomes. Even so, recent studies observed that AD patients have a more severe course. The main objective of this study is to confirm and discuss, through a systematic review, that being AD is a risk factor for disability accumulation and/or severe progression in patients with MS. A systematic review of published data in the last eleven years was performed, which evaluated clinical aspects and long term disability in patients with MS. Fourteen studies were included. Of these fourteen articles, thirteen observed a relationship between ancestry and poorer outcome of MS. African ancestry is a condition inherent in the patient and should be considered as an initial clinical characteristic affecting prognosis, and influencing which therapeutic decision to make in initial phases.

RESUMO

A prevalência da esclerose múltipla (EM) é maior em populações caucasianas (CA), o que limita a análise do impacto da Afrodescendencia (AD) nos desfechos da doença. Apesar disto, estudos recentes observaram que a AD determina um curso clínico mais severo. O principal objetivo deste estudo é confirmar e discutir, por meio de uma revisão sistemática, que a afrodescendência é um fator de risco para acúmulo de incapacidade e/ou progressão mais severa em pacientes com EM. Foi realizada uma revisão sistemática de trabalhos publicados nos últimos onze anos que avaliaram aspectos clínicos e incapacidade a longo prazo em pacientes com EM. Quatorze artigos foram incluídos. Entre eles, treze observaram uma relação entre AD e pior prognóstico da EM. AD é uma condição inerente ao paciente e deveria ser considerada, assim como as características clínicas relacionadas ao prognóstico, influenciando a decisão terapêutica a ser tomada nas fases iniciais da doença.

multiple sclerosis - disease progression - disability, Afro-descent

esclerose múltipla - progressão da doença - incapacidade, afrodescendente

Full Text

References

References
1 World Health Organization. Atlas multiple sclerosis resources in the world 2008. Geneva: World Health Organization; 2008.
2 Damasceno A, Von Glehn F, Brandão CO, Damasceno BP, Cendes F. Prognostic indicators for long-term disability in multiple sclerosis patients. J Neurol Sci. 2013;324(1-2):29-33. doi:10.1016/j.jns.2012.09.020
3 Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain. 2010;133(7):1914-29. doi:10.1093/brain/awq118
4 Hammond SR, McLeod JG, Macaskill P, English DR. Multiple sclerosis in Australia: prognostic factors. J Clin Neurosci. 2000;7(1):16-9. doi:10.1054/jocn.1998.0107
5 Amato MP, Ponziani G. A prospective study on the prognosis of multiple sclerosis. Neurol Sci. 2000;21(4 Suppl 2):S831-8. doi:10.1007/s100720070021
6 Confravreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126(4):770-82. doi:10.1093/brain/awg081
7 Debouverie M. Gender as a prognostic factor and its impact on the incidence of multiple sclerosis in Lorraine, France. J Neurol Sci. 2009;286(1-2):14-7. doi:10.1016/j.jns.2009.07.012
8 Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of secondary progressive MS. J Neurol Neurosurg Psychiatry. 2010;81(9):1039-43. doi:10.1136/jnnp.2010.208173
9 Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age and disability accumulation in multiple sclerosis. Neurology. 2011;77(12):1246-52. doi:10.1212/WNL.0b013e318230a17d
10 Scalfari A, Neuhaus A, Daumer M, DeLuca GC, Muraro PA, Ebers GC. Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurol. 2013;70(2):214-22. doi:10.1001/jamaneurol.2013.599
11 Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(3):606-16. doi:10.1093/brain/awl007
12 KingwellE, Marriott JJ, Jetté N, Pringsheim T, Makhani N, Morrow SA et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol. 2013;13(1):128. doi:10.1186/1471-2377-13-128
13 Johnson BA, Wang J, Taylor EM, Caillier SJ, Herbert J, Khan OA et al. Multiple sclerosis susceptibility alleles in African Americans. Genes Immun. 2010;11(4):343-50. doi:10.1038/gene.2009.81
14 Howard J, Battaglini M, Babb JS, Arienzo D, Holst B, Omari M et al. MRI correlates of disability in African-Americans with multiple sclerosis. PLoS One. 2012;7(8):e43061. doi:10.1371/journal.pone.0043061
15 Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2004;63(11):2039-45. doi:10.1212/01.WNL.0000145762.60562.5D
16 Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, Baier M, Rea DF, Apatoff BR et al. Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Mult Scler. 2003;9(3):293-8. doi:10.1191/1352458503ms909oa
17 Buchanan RJ, Zuniga MA, Carrillo-Zuniga G, Chakravorty BJ, Tyry T, Moreau RL et al. Comparisons of Latinos, African Americans, and Caucasians with multiple sclerosis. Ethn Dis. 2010;20(4):451-7.
18 Cree BAC, Al-Sabbagh A, Bennett R, Goodin D. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol. 2005;62(11):1681-3. doi:10.1001/archneur.62.11.1681
19 Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46(4):907-11.doi:10.1212/WNL.46.4.907
20 Kister I, Chamot E, Bacon JH, Niewczyk PM, De Guzman RA, Apatoff B et al. Rapid disease course in African Americans with multiple sclerosis. Neurology. 2010;75(3):217-23. doi:10.1212/WNL. 0b013e3181e8e72a
21 Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? Neurology. 2006;66(8):1235-40. doi:10.1212/01.wnl.0000208505.81912.82
22 Debouverie M, Lebrun C, Jeannin S, Pittion-Vouyovitch S, Roederer T, Vespignani H. More severe disability of North Africans vs Europeans with multiple sclerosis in France. Neurology. 2007;68(1):29-32. doi:10.1212/01.wnl.0000250347.51674.d7
23 Naismith RT, Trinkaus K, Cross AH. Phenotype and prognosis in African-Americans with multiple sclerosis: a retrospective chart review. Mult Scler. 2006;12(6):775-81. doi:10.1177/1352458506070923
24 Buchanan RJ, Martin RA, Zuniga M, Wang S, Kim M. Nursing home residents with multiple sclerosis: comparisons of African American residents to white residents at admission. Mult Scler. 2004;10(6):660-7. doi:10.1191/1352458504ms1086oa
25 Buchanan RJ, Martin RA, Wang S, Kim MS. Racial analysis of longer-stay nursing home residents with MS. Ethn Dis. 2006;16:160-5.
26 Kaufman MD, Johnson SK, Moyer D, Bivens J, Norton HJ. Multiple sclerosis: severity and progression rate in African Americans compared with whites. Am J Phys Med Rehabil. 2003;82(8):582-90. doi:10.1097/01.PHM.0000078199.99484.E2
27 Koffman J, Gao W, Goddard C, Burman R, Jackson D, Shaw P et al. Progression, symptoms and psychosocial concerns among those severely affected by multiple sclerosis: a mixed-methods cross-sectional study of Black Caribbean and White British people. PLoS One. 2013;8(10):e75431. doi:10.1371/journal.pone.0075431
28 Vasconcelos CCF, Santos GAC, Thuler LC, Camargo SM, Alvarenga RP. African ancestry is a predictor factors to secondary progression in clinical course of multiple sclerosis. ISRN Neurol. 2012;2012:410629. doi:10.5402/2012/410629
29 Vasconcelos CCF, Thuler LCS, Santos GAC, Alvarenga MP, Alvarenga MP, Camargo SMG et al. Differences in the progression of primary progressive multiple sclerosis in Brazilians of African descent versus white Brazilian patients. Mult Scler. 2010;16(5):597-603. doi:10.1177/1352458509360987
30 Alter M, Bethesd A. Multiple sclerosis in the negro. Arch Neurol. 1962;7(2):83-91. doi:10.1001/archneur.1962.04210020005001
31 Papais-Alvarenga RM, Santos CMM, Colin DD, Peixoto EC, Camargo SMGG. Esclerose múltipla (EM): influência do sexo e da etnia no perfil clínico de 88 pacientes no município do Rio de Janeiro. Rev Bras Neurol. 1995;31(2):89-98.
32 Alvarenga RMP, Vasconcelos CCF, Leon SVA et al. The impact of diagnostic criteria for neuromyelitis optica in patients with MS: a 10-year follow-up of the South Atlantic project. Mult Scler. 2014;20(3):374-81. doi:10.1177/1352458513495580
33 Callegaro D, Goldbaum M, Morais L, Tilbery CP, Moreira MA, Gabbai AA et al. The prevalence of multiple sclerosis in the city of São Paulo, Brazil, 1997. Acta Neurol Scand. 2001;104(4):208-13. doi:10.1034/j.1600-0404.2001.00372.x
34 Pena SD, Di Pietro G, Fuchshuber-Moraes M, Genro JP, Hutz MH, Kehdy FS et al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS One. 2011;6(2):e17063. doi:10.1371/journal.pone.0017063
35 Weinstock-Guttman B, Ramanathan M, Hashmi K, Abdelrahman N, Hojnacki D, Dwyer MG et al. Increased tissue damage and lesion volumes in African Americans with multiple sclerosis. Neurology. 2010;74(7):538-44. doi:10.1212/WNL.0b013e3181cff6fb
36 Rinker JR 2nd, Trinkaus K, Naismith RT, Cross AH. Higher IgG index found in African Americans versus Caucasians with multiple sclerosis. Neurology. 2007;69(1):68-72. doi:10.1212/01.wnl.0000265057.79843.d9
37 Gama PD, Machado LR, Livramento JÁ, Gomes HR, Adoni T, Morales RR et al. Oligoclonal bands in cerebrospinal fluid of black patients with multiple sclerosis. BioMed Res Int. 2015;2015:217961. doi:10.1155/2015/217961
38 Jeannin S, Deschamps R, Chausson N, Cabre P. Response to interferon-Beta treatment in afro-caribbeans with multiple sclerosis. Mult Scler Int. 2011;950126. doi:10.1155/2011/950126
39 Klineova S, Nicholas J, Walker A. Response to disease modifying therapies in African Americans with multiple sclerosis. Ethn Dis. 2012;22(2):221-5.